Browse
Explore clinical trials and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
86925 trials found · Page 90 of 4347
-
Three-Drug attack on deadly skin cancer shows promise
Disease control OngoingThe purpose of this study is to learn about the effects of three study medicines (encorafenib, binimetinib, and pembrolizumab) given together for the treatment of melanoma that: * is advanced or metastatic (spread to other parts of the body); * has a certain type of abnormal gen…
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Apr 23, 2026 12:44 UTC
-
New shot shows promise against tough lymphoma in major trial
Disease control OngoingThe purpose of this trial is to find out if epcoritamab, also known as EPKINLY™ and GEN3013, is safe and works well as treatment for participants with DLBCL that are not responding to treatment, have grown in size, or have come back following treatment with at least 1 prior syste…
Phase: PHASE3 • Sponsor: Genmab • Aim: Disease control
Last updated Apr 26, 2026 19:35 UTC
-
Could a 'Smart' transplant free blood cancer patients from lifelong drugs?
Disease control Recruiting nowThis research study is evaluating the safety and efficacy of the IS-free Treg-cell graft-engineered haplo transplant method in people with relapsed/refractory and Ultra-high risk acute myeloid leukemia (AML) and/or myelodysplastic syndromes (MDS) receiving a haploidentical donor …
Phase: PHASE1 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Apr 24, 2026 16:17 UTC
-
New hope for advanced anal cancer: immunotherapy combo shows promise
Disease control CompletedThis study is a Phase 3 global, multicenter, placebo-controlled double-blind randomized study that will enroll participants with inoperable locally recurrent or metastatic SCAC not previously treated with systemic chemotherapy.
Phase: PHASE3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Apr 08, 2026 12:03 UTC
-
Brain-Controlling implant offers new hope for tough arthritis cases
Disease control OngoingThe RESET-RA study will assess the safety and efficacy of the SetPoint System (study device) for the treatment of adult patients with active, moderate to severe rheumatoid arthritis who have had an inadequate response or intolerance to biologic or targeted synthetic Disease-Modif…
Phase: PHASE3 • Sponsor: SetPoint Medical Corporation • Aim: Disease control
Last updated Apr 21, 2026 12:44 UTC
-
New combo therapy aims to fight Hard-to-Treat head and neck cancer
Disease control Recruiting nowAn open-label, controlled, multi-site, interventional, 2-arm, Phase II/III trial of BNT113 in combination with pembrolizumab vs pembrolizumab monotherapy as first line treatment in patients with unresectable recurrent or metastatic HPV16+ HNSCC expressing programmed cell death li…
Phase: PHASE2, PHASE3 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Apr 26, 2026 19:38 UTC
-
New shot could tame tough leukemia in teens and adults
Disease control Recruiting nowThe Phase I part of the study aims to evaluate the safety, efficacy, and tolerability of subcutaneous (SC) blinatumomab for treatment of Relapsed or Refractory B cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL), to determine the maximum tolerated dose (MTD), and recommende…
Phase: PHASE1, PHASE2 • Sponsor: Amgen • Aim: Disease control
Last updated Apr 24, 2026 16:06 UTC
-
Double attack on tough lymphoma: immune cells plus targeted pill
Disease control Recruiting nowThis phase II trial investigates the side effects of CD19 chimeric antigen receptor (CAR) T cells and acalabrutinib, and to see how well they work in treating patients with mantle cell lymphoma that has come back (relapsed) or does not respond to treatment (refractory). T cells a…
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Apr 26, 2026 20:00 UTC
-
New drug targets Cancer's genetic weakness across multiple tumor types
Disease control OngoingThis is an open-label, multi-center, single arm, Phase II study to evaluate the efficacy and safety of T-DXd for the treatment of unresectable and/or metastatic solid tumors harboring specific HER2 activating mutations regardless of tumor histology. The target population are pati…
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Apr 16, 2026 12:47 UTC
-
Major trial aims to extend lives in advanced stomach cancer
Disease control OngoingThe purpose of this study is to assess the efficacy and safety of lenvatinib (E7080/MK-7902) plus pembrolizumab (MK-3475) plus chemotherapy compared with chemotherapy alone in participants with advanced/metastatic gastroesophageal cancer. The primary study hypotheses are that le…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Apr 20, 2026 16:14 UTC
-
One-Shot gene therapy could end monthly eye needles for wet AMD
Disease control Recruiting nowABBV-RGX-314 (also known as RGX-314) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD or nAMD). Wet AMD is characterized by loss of vision due to new, leaky blood vessel formation in the retina. W…
Phase: PHASE2, PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Apr 24, 2026 16:20 UTC
-
Meningitis shot may block gonorrhea: 2,600-person trial underway
Prevention OngoingThis is a Phase II, randomized, observer-blind, placebo-controlled, multi-site trial of the FDA licensed rMenB+OMV NZ vaccine, Bexsero. The targeted study population is men and women 18-50 years of age who are disproportionately vulnerable to N. gonorrhoeae infection. Approximate…
Phase: PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Prevention
Last updated Apr 26, 2026 19:39 UTC
-
New hope: immune therapy targets aggressive recurrent brain tumors
Disease control OngoingThis phase II trial studies the effect of immunotherapy drugs (ipilimumab and nivolumab) in treating patients with glioma that has come back (recurrent) and carries a high number of mutations (mutational burden). Cancer is caused by changes (mutations) to genes that control the w…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
New drug combo aims to stop breast Cancer's return in High-Risk women
Disease control OngoingPOETIC-A is a phase 3 trial which targets post-menopausal primary breast cancer patients with a high 5-year risk of relapse as determined by a high Ki67 after 2 weeks aromatase inhibitor therapy pre-surgery. Eligible patients will be randomised to standard adjuvant endocrine ther…
Phase: PHASE3 • Sponsor: Institute of Cancer Research, United Kingdom • Aim: Disease control
Last updated Apr 20, 2026 16:17 UTC
-
Leukemia patients try life without daily pills in groundbreaking 'Drug Holiday' study
Disease control Recruiting nowThis is a single-arm, phase II study to evaluate safety and efficacy of tyrosine kinase inhibitor (TKI) cessation for chronic myeloid leukemia (CML) patients with stable molecular response in a real world population.
Phase: PHASE2 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Apr 07, 2026 14:37 UTC
-
New hope for Tough-to-Treat lung cancer: experimental drug challenges standard chemo
Disease control OngoingThis study will evaluate the efficacy, safety, and pharmacokinetics of DS-1062a versus docetaxel in participants with previously treated advanced or metastatic non-small cell lung cancer (NSCLC) with or without actionable genomic alterations.
Phase: PHASE3 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Apr 20, 2026 16:16 UTC
-
New drug combo shows promise in tough lung cancer
Disease control OngoingThe purpose of this multicenter study in China is to evaluate the safety and efficacy of tiragolumab plus atezolizumab and carboplatin and etoposide (CE) compared with placebo plus atezolizumab and CE in participants with untreated extensive-stage small cell lung cancer.
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Apr 26, 2026 19:36 UTC
-
New Two-Drug attack on childhood leukemia that returns
Disease control Recruiting nowThis phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients with relapsed B-ALL are included in this…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 20, 2026 16:16 UTC
-
New Two-Pronged attack tested for advanced blood cancer
Disease control OngoingThe purpose of this study is to identify the recommended Phase 2 regimen(s) (RP2R\[s\]) and schedule for the study treatment (Part 1), to characterize the safety of the RP2R(s) for the study treatment (Part 2) and to evaluate the anticancer activity of talquetamab + teclistamab i…
Phase: PHASE1, PHASE2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Apr 17, 2026 16:11 UTC
-
New combo therapy battles advanced lung cancer in major trial
Disease control CompletedThe purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of tiragolumab in combination with atezolizumab plus pemetrexed and carboplatin/cisplatin (Arm A) compared with placebo in combination with pembrolizumab plus pemetrexed and carboplatin/cisplatin …
Phase: PHASE2, PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Mar 18, 2026 14:40 UTC